Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer
| العنوان: | Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer |
|---|---|
| المؤلفون: | Roula Albadine, Rosalyn A. Juergens, Normand Blais, Charles Butts, Victor Cohen, Zhaolin Xu, Scott A. Laurie, Suzanne Kamel-Reid, Shantanu Banerji, Geoffrey Liu, D.G. Bebb, Diana N. Ionescu, Wojciech Morzycki, P. Cheung, Ming-Sound Tsao, Jason Agulnik, Parneet Cheema, Jean Deschenes, Barbara Melosky, D. Bethune, V. Hirsh |
| المصدر: | Current Oncology Volume 23 Issue 3 Pages 3120-200 |
| بيانات النشر: | Multidisciplinary Digital Publishing Institute, 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | 0301 basic medicine, Oncology, medicine.medical_specialty, medicine.drug_class, Population, ALK Pathway, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, hemic and lymphatic diseases, medicine, Anaplastic lymphoma kinase, education, Lung cancer, targeted inhibition, education.field_of_study, molecular testing, Crizotinib, Ceritinib, business.industry, anaplastic lymphoma kinase, medicine.disease, respiratory tract diseases, ALK inhibitor, 030104 developmental biology, Practice Guideline, ALK, non-small-cell lung cancer, 030220 oncology & carcinogenesis, business, Brain metastasis, medicine.drug |
| الوصف: | Anaplastic lymphoma kinase (alk) is an oncogenic driver in non-small-cell lung cancer (nsclc). Chromosomal rearrangements involving the ALK gene occur in up to 4% of nonsquamous nsclc patients and lead to constitutive activation of the alk signalling pathway. ALK-positive nsclc is found in relatively young patients, with a median age of 50 years. Patients frequently have brain metastasis. Targeted inhibition of the alk pathway prolongs progression-free survival in patients with ALK-positive advanced nsclc. The results of several recent clinical trials confirm the efficacy and safety benefit of crizotinib and ceritinib in this population. Canadian oncologists support the following consensus statement: All patients with advanced nonsquamous nsclc (excluding pure neuroendocrine carcinoma) should be tested for the presence of an ALK rearrangement. If an ALK rearrangement is present, treatment with a targeted alk inhibitor in the first-line setting is recommended. As patients become resistant to first-generation alk inhibitors, other treatments, including second-generation alk inhibitors can be considered. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1718-7729 |
| DOI: | 10.3747/co.23.3120 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::328133a09aa355a7b2171e1b3d83649d |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....328133a09aa355a7b2171e1b3d83649d |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17187729 |
|---|---|
| DOI: | 10.3747/co.23.3120 |